Orexo AB (publ) (STO:ORX)
18.60
-0.70 (-3.63%)
Apr 29, 2026, 10:22 AM CET
Orexo AB Revenue
In the year 2025, Orexo AB had annual revenue of 26.00M SEK, down -12.46%. Orexo AB had revenue of 3.30M in the quarter ending December 31, 2025.
Revenue
26.00M
Revenue Growth
-12.46%
P/S Ratio
25.92
Revenue / Employee
351.35K
Employees
74
Market Cap
673.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.00M | -3.70M | -12.46% |
| Dec 31, 2024 | 29.70M | -609.10M | -95.35% |
| Dec 31, 2023 | 638.80M | 14.50M | 2.32% |
| Dec 31, 2022 | 624.30M | 59.30M | 10.50% |
| Dec 31, 2021 | 565.00M | -98.60M | -14.86% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Enzymatica AB | 53.90M |
| Dicot Pharma AB | 200.00K |
| Nanexa AB | 55.94M |
| Moberg Pharma AB | 13.54M |
| Cinclus Pharma Holding AB | 57.47M |
| EQL Pharma AB | 425.75M |
| Cereno Scientific AB | 44.27M |
| Klaria Pharma Holding AB (publ.) | 8.99M |
Orexo AB News
- 5 weeks ago - Orexo AB Transcript: R&D Day - Transcripts
- 7 weeks ago - Invitation & Agenda: Orexo R&D Day on March 24 - PRNewsWire
- 7 weeks ago - Orexo changes the organizational structure and management team to increase focus on development of new products - PRNewsWire
- 2 months ago - Orexo AB Earnings Call Transcript: Q4 2025 - Transcripts
- 4 months ago - Orexo AB Transcript: Investor Update - Transcripts
- 6 months ago - Orexo AB Earnings Call Transcript: Q3 2025 - Transcripts
- 7 months ago - Orexo AB Transcript: Investing in Life Science 2025 - Transcripts
- 8 months ago - Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication - PRNewsWire